Claims for Patent: 8,019,551
✉ Email this page to a colleague
Summary for Patent: 8,019,551
Title: | Biological dataset profiling of asthma and atopy |
Abstract: | Methods and systems for evaluating biological dataset profiles relating to asthma and other atopic conditions are provided, where datasets comprising information for multiple cellular parameters are compared and identified, and used in the evaluation of candidate pharmacologic agents for suitability as therapeutic agents. |
Inventor(s): | Rosler; Elen S. (Mountain View, CA), Kunkel; Eric J. (San Mateo, CA), Privat; Sylvie (South San Francisco, CA), Melrose; Jennifer (La Honda, CA), Fischer; Melissa (Jackson, OR), Berg; Ellen L. (Palo Alto, CA) |
Assignee: | Bioseek LLC (Burlingame, CA) |
Application Number: | 10/590,751 |
Patent Claims: | 1. A method for characterization of a candidate agent according to its effect on allergic/atopic conditions, the method comprising: contacting said candidate agent with an
asthma/atopy context system selected from (a) primary human umbilical vein endothelial cells (HUVEC) in the presence of IL-4 and histamine with at least three different cellular parameters selected from CD55, VCAM-1, P-selectin, Eotaxin-3, MCP-1, VEGF
receptor 2 and uPAR (CD87); (b) HUVEC and T cells in the presence of IL-2 and superantigen with at least three different parameters selected from IFN-.gamma., TNF-alpha, IL-2, IL-4, IL-5, IL-8, IL10, IL-13, LT-alpha, CCR4, CCR5, CXCR3, IL-4Ralpha,
CD11c, CD38, CD40, CD69, E-Selectin, Eotaxin-3, CD106, CD134, CD150, CD137, CD69, CD200, B7-H1, B7-H2, MIG and CD87; (c) Human neonatal fibroblasts (HDFn) in the presence of TNF, IL-1, IFN and TGF.beta. with at least three different parameters selected
from ICAM, VCAM, CD40, CD90, IP-10, MCP-1, Collagen I, Mig, m-CSF, TIMP-2, PAI-I, and IL-8 (d) HDFn in the presence of TGF.beta. with at least three different parameters selected from CD90, Collagen I, Collagen III, HLA-DR, PAI-I, and VCAM (e) human
bronchial epithelial cells and HDFn in the presence of IL-4 and TNF.alpha. with at least three different parameters selected from ICAM-1, IL-1a, IP-10, TGF-.beta., MIG, HLA-DR, PAI-1, I-TAC, MMP-1, MMP-9, CD87 and Keratin 8/18 (f) primary human
umbilical artery smooth muscle cells in the presence of IL-4 and histamine with at least three different parameters selected from VCAM, CD40, HLA-DR, ICAM, IL-8, MCP-1, M-CSF, MIG, Thrombomodulin, and uPAR; (g) primary human umbilical artery smooth
muscle cells in the presence of IL-1, TNF-.alpha. and IFN.gamma. with at least three different parameters selected from VCAM, CD40, HLA-DR, ICAM, IL-8, MCP-1, M-CSF, MIG, Thrombomodulin, and uPAR; (h) human bronchial epithelial cells in the presence
of IL-1.beta., TNF.alpha. and IFN-.gamma. with at least three different parameters selected from ICAM-1, IL-1a, IP-10, TGF-.beta., MIG, HLA-DR, PAI-1, I-TAC, MMP-1, MMP-9, CD87 and Keratin 8/18; and (i) human bronchial epithelial cells in the presence
of IL-4, IL-13 and TNF.alpha. with at least three different parameters selected from Eotaxin-3, ICAM-1, IL-1a, IL-8, TGF-.beta., PAI-1, MMP-9, uPA and Keratin 8/18; measuring changes in parameters as a result of introduction of said candidate agent in
said at least three different parameters; deriving a biological dataset from said changes in parameters, wherein said biological dataset comprises control data from said asthma/atopy context system lacking said candidate agent; comparing said
biological dataset to a reference biological dataset that includes predetermined agents that target specific asthma/atopy pathways to determine the presence of variation, wherein the presence or absence of variation from said reference biological
datasets provides a characterization of said candidate agent's effect on allergic/atopic conditions.
2. The method according to claim 1, wherein said candidate agent is a polynucleotide or analog thereof. 3. The method according to claim 1, wherein said candidate agent is a drug or polypeptide. 4. A method for characterization of a candidate agent according to its effect on allergic/atopic conditions, the method comprising: contacting said candidate agent with a plurality of asthma/atopy context systems selected from (a) primary human umbilical vein endothelial cells (HUVEC) in the presence of IL-4 and histamine with at least three different cellular parameters selected from CD55, VCAM-1, P-selectin, Eotaxin-3, MCP-1, VEGF receptor 2 and uPAR (CD87); (b) HUVEC and T cells in the presence of IL-2 and superantigen with at least three different parameters selected from IFN-.gamma., TNF-alpha, IL-2, IL-4, IL-5, IL-8, IL10, IL-13, LT-alpha, CCR4, CCR5, CXCR3, IL-4Ralpha, CD11c, CD38, CD40, CD69, E-Selectin, Eotaxin-3, CD106, CD134, CD150, CD137, CD69, CD200, B7-H1, B7-H2, MIG and CD87; (c) Human neonatal fibroblasts (HDFn) in the presence of TNF, IL-1, IFN and TGF.beta. with at least three different parameters selected from ICAM, VCAM, CD40, CD90, IP-10, MCP-1, Collagen I, Mig, m-CSF, TIMP-2, PAI-I, and IL-8 (d) HDFn in the presence of TGF.beta. with at least three different parameters selected from CD90, Collagen I, Collagen III, HLA-DR, PAI-I, and VCAM (e) human bronchial epithelial cells and HDFn in the presence of IL-4 and TNF.alpha. with, at least three different parameters selected from ICAM-1, IL-1a, IP-10, TGF-.beta., MIG, HLA-DR, PAI-1, I-TAC, MMP-1, MMP-9, CD87 and Keratin 8/18 (f) primary human umbilical artery smooth muscle cells in the presence of IL-4 and histamine with at least three different parameters selected from VCAM, CD40, HLA-DR, ICAM, IL-8, MCP-1, M-CSF, MIG, Thrombomodulin, and uPAR; (g) primary human umbilical artery smooth muscle cells in the presence of IL-1, TNF-.alpha. and IFN.gamma. with at least three different parameters selected from VCAM, CD40, HLA-DR, ICAM, IL-8, MCP-1, M-CSF, MIG, Thrombomodulin, and uPAR; (h) human bronchial epithelial cells in the presence of IL-1.beta., TNF.alpha. and IFN-.gamma. with at least three different parameters selected from ICAM-1, IL-1a, IP-10, TGF-.beta., MIG, HLA-DR, PAI-1, I-TAC, MMP-1, MMP-9, CD87 and Keratin 8/18; and (i) human bronchial epithelial cells in the presence of IL-4, IL-13 and TNF.alpha. with at least three different parameters selected from Eotaxin-3, ICAM-1, IL-1a, IL-8, TGF-.beta., PAI-1, MMP-9, uPA and Keratin 8/18; measuring changes in parameters as a result of introduction of said candidate agent in said at least three different parameters; deriving a biological dataset from said changes in parameters, wherein said biological dataset comprises control data from asthma/atopy context systems lacking said candidate agent; comparing said biological dataset to a reference biological dataset that includes predetermined agents that target specific asthma/atopy pathways to determine the presence of variation, wherein the presence or absence of variation from said reference biological datasets provides a characterization of said candidate agent's effect on allergic/atopic conditions. 5. A method for characterization of a candidate agent according to its effect on allergic/atopic conditions, the method comprising: contacting said candidate agent with a plurality of asthma/atopy context systems selected from (a) primary human umbilical vein endothelial cells (HUVEC) in the presence of IL-4 and histamine with at least three different cellular parameters selected from CD55, VCAM-1, P-selectin, Eotaxin-3, MCP-1, VEGF receptor 2 and uPAR (CD87); (b) HUVEC and T cells in the presence of IL-2 and superantigen with at least three different parameters selected from IFN-.gamma., TNF-alpha, IL-2, IL-4, IL-5, IL-8, IL10, IL-13, LT-alpha, CCR4, CCR5, CXCR3, IL-4Ralpha, CD11c, CD38, CD40, CD69, E-Selectin, Eotaxin-3, CD106, CD134, CD150, CD137, CD69, CD200, B7-H1, B7-H2, MIG and CD87; (c) Human neonatal fibroblasts (HDFn) in the presence of TNF, IL-1, IFN and TGF.beta. with at least three different parameters selected from ICAM, VCAM, CD40, CD90, IP-10, MCP-1, Collagen I, Mig, m-CSF, TIMP-2, PAI-I, and IL-8 (d) HDFn in the presence of TGF.beta. with at least three different parameters selected from CD90, Collagen I, Collagen III, HLA-DR, PAI-I, and VCAM (e) human bronchial epithelial cells and HDFn in the presence of IL-4 and TNF.alpha. with at least three different parameters selected from ICAM-1, IL-1a, IP-10, TGF-.beta., MIG, HLA-DR, PAI-1, I-TAC, MMP-1, MMP-9, CD87 and Keratin 8/18 (f) primary human umbilical artery smooth muscle cells in the presence of IL-4 and histamine with at least three different parameters selected from VCAM, CD40, HLA-DR, ICAM, IL-8, MCP-1, M-CSF, MIG, Thrombomodulin, and uPAR; (g) primary human umbilical artery smooth muscle cells in the presence of IL-1, TNF-.alpha. and IFN.gamma. with at least three different parameters selected from VCAM, CD40, HLA-DR, ICAM, IL-8, MCP-1, M-CSF, MIG, Thrombomodulin, and uPAR; (h) human bronchial epithelial cells in the presence of IL-.beta., TNF.alpha. and IFN-.gamma. with at least three different parameters selected from ICAM-1, IL-1a, IP-10, TGF-.beta., MIG, HLA-DR, PAI-1, I-TAC, MMP-1, MMP-9, CD87 and Keratin 8/18; and (i) human bronchial epithelial cells in the presence of IL-4, IL-13 and TNF.alpha. with at least three different parameters selected from Eotaxin-3, ICAM-1, IL-1a, IL-8, TGF-.beta., PAI-1, MMP-9, uPA and Keratin 8/18; measuring changes in parameters as a result of introduction of said candidate agent in said at least three different parameters; deriving a biological dataset from said changes in parameters, wherein said biological dataset comprises control data from said asthma/atopy context system lacking said candidate agent; comparing said biological dataset to a reference biological dataset that includes predetermined agents that target specific asthma or atopy pathways to determine the presence of variation, wherein the presence or absence of variation from said reference biological datasets provides a characterization of said candidate agent's effect on allergic/atopic conditions wherein said plurality of systems are concatenated for simultaneous analysis. |
Details for Patent 8,019,551
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | 03/13/1924 | ⤷ Try a Trial | 2040-01-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.